Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
How safe and effective is tumor necrosis factor (TNF) antagonism for
psoriatic arthritis (PsA) in the real world? Using a British biologics
registry, this group found that approximately 70% of patients exhibited a
clinical response, without evidence for toxicity in excess of that observed
with conventional therapy.
» Read an expert review of this paper